TScan Therapeutics, Inc. (TCRX)
NASDAQ: TCRX · Real-Time Price · USD
0.7962
+0.0330 (4.32%)
At close: Aug 7, 2026, 4:00 PM EDT
0.8003
+0.0041 (0.51%)
After-hours: Aug 7, 2026, 7:34 PM EDT

TScan Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
9.1410.332.8221.0513.5410.14
Revenue Growth
106.65%266.65%-86.62%55.52%33.47%834.65%
Gross Profit
9.1410.332.8221.0513.5410.14
Operating Income
-128.7-135.81-134.82-93.46-66.64-48.64
Net Income
-124.31-129.77-127.5-89.22-66.22-48.63
Earnings Per Share
-0.96-1.00-1.14-1.36-2.75-4.17
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
128.06152.41290.11192.04120.03161.41
Total Debt
92.5494.1497.3892.4385.986.04
Net Cash (Debt)
35.5258.27192.7399.6134.04155.36
Net Cash Growth
-77.03%-69.77%93.48%192.60%-78.09%467.91%
Net Cash Per Share
0.270.451.721.521.4213.32

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-122.01-135.32-110.82-61.36-66.5-48.68
Capital Expenditures
-2.95-4.41-3.83-3.15-4.23-9.94
Free Cash Flow
-124.96-139.73-114.65-64.5-70.73-58.62
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-1408.73%-1315.38%-4787.68%-444.00%-492.32%-479.65%
Pretax Margin
-1360.61%-1256.81%-4527.66%-423.86%-489.26%-479.49%
Profit Margin
-1360.61%-1256.81%-4527.66%-423.86%-489.26%-479.49%
FCF Margin
-1367.74%-1353.28%-4071.27%-306.45%-522.56%-578.03%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
5.705.5161.0913.252.7710.61